CommentOptimal adjuvant endocrine therapy for breast cancer
References (10)
- et al.
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial
Lancet
(2013) - et al.
Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial
Lancet Oncol
(2017) - et al.
Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population
Lancet Oncol
(2013) Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials
Lancet
(2015)- et al.
Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO clinical practice guideline focused update
J Clin Oncol
(2019)
There are more references available in the full text version of this article.
Cited by (5)
EZH2 Protein Expression in Estrogen Receptor Positive Invasive Breast Cancer Treated With Neoadjuvant Endocrine Therapy: An Exploratory Study of Association With Tumor Response
2022, Applied Immunohistochemistry and Molecular MorphologyCan a Late Interception by Circulating Tumor DNA Deliver a Win in Estrogen Receptor-Positive Early Breast Cancer?
2022, Journal of Clinical Oncology
© 2021 Elsevier Ltd. All rights reserved.